Published in J Cardiovasc Electrophysiol on May 01, 2006
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation (2007) 2.90
Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm (2011) 2.02
Excitation-contraction coupling and mitochondrial energetics. Basic Res Cardiol (2007) 1.74
Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels. Am J Physiol Heart Circ Physiol (2010) 1.66
Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action. Circulation (2012) 1.56
Deranged sodium to sudden death. J Physiol (2015) 1.51
Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. Eur J Heart Fail (2006) 1.47
Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm (2008) 1.46
Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations. Heart Rhythm (2011) 1.44
Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle. J Mol Med (Berl) (2011) 1.43
Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res (2012) 1.39
Modulation of late sodium current by Ca2+, calmodulin, and CaMKII in normal and failing dog cardiomyocytes: similarities and differences. Am J Physiol Heart Circ Physiol (2008) 1.36
Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure. J Mol Med (Berl) (2010) 1.25
The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J (2008) 1.25
The cardiac persistent sodium current: an appealing therapeutic target? Br J Pharmacol (2007) 1.23
Late sodium current in failing heart: friend or foe? Prog Biophys Mol Biol (2007) 1.23
Use-dependent block of cardiac late Na(+) current by ranolazine. Heart Rhythm (2009) 1.23
Designing and encoding models for synthetic biology. J R Soc Interface (2009) 1.23
The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J (2009) 1.21
Atrial-selective sodium channel blockers: do they exist? J Cardiovasc Pharmacol (2008) 1.18
Late sodium current contributes to diastolic cell Ca2+ accumulation in chronic heart failure. J Physiol Sci (2010) 1.18
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vasc Health Risk Manag (2010) 1.16
Ranolazine: a new approach to treating an old problem. Tex Heart Inst J (2010) 1.15
Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. Cardiovasc Res (2007) 1.15
Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol (2009) 1.13
Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent block. Am J Physiol Heart Circ Physiol (2011) 1.08
Diastolic dysfunction and arrhythmias caused by overexpression of CaMKIIδ(C) can be reversed by inhibition of late Na(+) current. Basic Res Cardiol (2010) 1.06
Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening. Circ Res (2013) 1.04
The arrhythmogenic consequences of increasing late INa in the cardiomyocyte. Cardiovasc Res (2013) 1.03
Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol (2008) 1.03
Voltage-Gated Sodium Channel Phosphorylation at Ser571 Regulates Late Current, Arrhythmia, and Cardiac Function In Vivo. Circulation (2015) 0.98
Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium. Br J Pharmacol (2007) 0.98
Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation. Ann N Y Acad Sci (2008) 0.97
Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability. Mol Pain (2010) 0.97
Role of late sodium current as a potential arrhythmogenic mechanism in the progression of pressure-induced heart disease. J Mol Cell Cardiol (2013) 0.96
Late sodium current is a new therapeutic target to improve contractility and rhythm in failing heart. Cardiovasc Hematol Agents Med Chem (2008) 0.96
Pathophysiology of the cardiac late Na current and its potential as a drug target. J Mol Cell Cardiol (2011) 0.95
Late Na+ current produced by human cardiac Na+ channel isoform Nav1.5 is modulated by its beta1 subunit. J Physiol Sci (2009) 0.95
Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: II. Insights from a mathematical model. Am J Physiol Heart Circ Physiol (2011) 0.94
Dynamics of the late Na(+) current during cardiac action potential and its contribution to afterdepolarizations. J Mol Cell Cardiol (2013) 0.94
Simulation and mechanistic investigation of the arrhythmogenic role of the late sodium current in human heart failure. PLoS One (2012) 0.93
The role of late I Na in development of cardiac arrhythmias. Handb Exp Pharmacol (2014) 0.93
Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967. Heart Rhythm (2013) 0.92
Race, common genetic variation, and therapeutic response disparities in heart failure. JACC Heart Fail (2014) 0.91
Post-transcriptional silencing of SCN1B and SCN2B genes modulates late sodium current in cardiac myocytes from normal dogs and dogs with chronic heart failure. Am J Physiol Heart Circ Physiol (2011) 0.91
Role of sodium and calcium dysregulation in tachyarrhythmias in sudden cardiac death. Circ Res (2015) 0.91
Resveratrol attenuates the Na(+)-dependent intracellular Ca(2+) overload by inhibiting H(2)O(2)-induced increase in late sodium current in ventricular myocytes. PLoS One (2012) 0.90
Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine. J Mol Cell Cardiol (2009) 0.90
Molecular identity of the late sodium current in adult dog cardiomyocytes identified by Nav1.5 antisense inhibition. Am J Physiol Heart Circ Physiol (2008) 0.89
Role of late sodium channel current block in the management of atrial fibrillation. Cardiovasc Drugs Ther (2013) 0.89
From the Hodgkin-Huxley axon to the virtual heart. J Physiol (2006) 0.89
Contribution of sodium channel neuronal isoform Nav1.1 to late sodium current in ventricular myocytes from failing hearts. J Physiol (2014) 0.84
Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation. Europace (2012) 0.82
Electrophysiological profile of propiverine--relationship to cardiac risk. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.81
In silico assessment of drug safety in human heart applied to late sodium current blockers. Channels (Austin) (2014) 0.81
Ketamine attenuates the Na(+)-dependent Ca(2+) overload in rabbit ventricular myocytes in vitro by inhibiting late Na(+) and L-type Ca(2+) currents. Acta Pharmacol Sin (2015) 0.80
Effects of the antianginal drug, ranolazine, on the brain sodium channel Na(V)1.2 and its modulation by extracellular protons. Br J Pharmacol (2013) 0.80
Electrophysiological and structural remodeling in heart failure modulate arrhythmogenesis. 1D simulation study. PLoS One (2014) 0.80
Novel pharmacological approaches for antiarrhythmic therapy. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.80
Sodium overload due to a persistent current that attenuates the arrhythmogenic potential of a novel LQT3 mutation. Front Pharmacol (2013) 0.80
Experimentally-Based Computational Investigation into Beat-To-Beat Variability in Ventricular Repolarization and Its Response to Ionic Current Inhibition. PLoS One (2016) 0.79
Complex excitation dynamics underlie polymorphic ventricular tachycardia in a transgenic rabbit model of long QT syndrome type 1. Heart Rhythm (2014) 0.79
Emerging clinical role of ranolazine in the management of angina. Ther Clin Risk Manag (2010) 0.79
Late cardiac sodium current can be assessed using automated patch-clamp. F1000Res (2014) 0.79
Selective inhibition of persistent sodium current by F 15845 prevents ischaemia-induced arrhythmias. Br J Pharmacol (2010) 0.79
Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure. Circ Heart Fail (2014) 0.79
The Use of Ratiometric Fluorescence Measurements of the Voltage Sensitive Dye Di-4-ANEPPS to Examine Action Potential Characteristics and Drug Effects on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Toxicol Sci (2016) 0.79
Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine. Front Pharmacol (2013) 0.78
New antiarrhythmic targets to control intracellular calcium handling. Neth Heart J (2014) 0.78
Voltage-gated sodium channels: pharmaceutical targets via anticonvulsants to treat epileptic syndromes. Channels (Austin) (2013) 0.77
Cardiac resynchronization therapy improves altered Na channel gating in canine model of dyssynchronous heart failure. Circ Arrhythm Electrophysiol (2013) 0.77
Calpain inhibition reduces amplitude and accelerates decay of the late sodium current in ventricular myocytes from dogs with chronic heart failure. PLoS One (2013) 0.77
New treatment options for late Na current, arrhythmias, and diastolic dysfunction. Curr Heart Fail Rep (2012) 0.77
Regulation of intracellular Na(+) in health and disease: pathophysiological mechanisms and implications for treatment. Glob Cardiol Sci Pract (2013) 0.77
Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study. Pulm Circ (2015) 0.76
Late Sodium Current in Human Atrial Cardiomyocytes from Patients in Sinus Rhythm and Atrial Fibrillation. PLoS One (2015) 0.76
Refractory atrial fibrillation effectively treated with ranolazine. Indian Heart J (2014) 0.76
Antagonism of Nav channels and α1-adrenergic receptors contributes to vascular smooth muscle effects of ranolazine. Sci Rep (2015) 0.75
Effects of ranolazine on torsades de pointes tachycardias in a healthy isolated rabbit heart model. Cardiovasc Ther (2014) 0.75
The Power of One: a Highly Detailed, Log-Based, Case Example that Clearly Demonstrates the Effective Use of Ranolazine for the Control of Progressive Atrial Fibrillationn. J Atr Fibrillation (2010) 0.75
Changes in Intracellular Na+ following Enhancement of Late Na+ Current in Virtual Human Ventricular Myocytes. PLoS One (2016) 0.75
Suppression of frequent ventricular ectopy in a patient with hypertrophic heart disease with ranolazine: a case report. Indian Pacing Electrophysiol J (2011) 0.75
Pulmonary Vein Sleeves as a Pharmacologic Model for the Study of Atrial Fibrillation. Electrofisiol Arritm (2010) 0.75
Electrophysiological Changes of the Atrium in Patients with Lone Paroxysmal Atrial Fibrillation. J Atr Fibrillation (2010) 0.75
Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure. Diseases (2017) 0.75
Dynamics of sodium current mediated early afterdepolarizations. Heliyon (2017) 0.75
Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure. Curr Heart Fail Rep (2017) 0.75
Lidocaine block of cardiac sodium channels. J Gen Physiol (1983) 5.13
Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation (2004) 4.13
Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res (1987) 3.86
What causes sudden death in heart failure? Circ Res (2004) 3.44
Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res (1999) 3.43
Alterations of K+ currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res (1993) 2.94
Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ Res (1996) 2.91
Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J Mol Cell Cardiol (2005) 2.60
Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol (2004) 2.31
Novel, ultraslow inactivating sodium current in human ventricular cardiomyocytes. Circulation (1998) 2.13
A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol (1991) 2.08
Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium. Circulation (2002) 1.95
Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol (2004) 1.94
Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther (2004) 1.88
Gating of the late Na+ channel in normal and failing human myocardium. J Mol Cell Cardiol (2002) 1.88
Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current. Cell Mol Life Sci (1999) 1.65
Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation (1995) 1.39
Late sodium current is a novel target for amiodarone: studies in failing human myocardium. J Mol Cell Cardiol (2001) 1.34
The sarcoplasmic reticulum and the Na+/Ca2+ exchanger both contribute to the Ca2+ transient of failing human ventricular myocytes. Circ Res (1999) 1.32
A multi-modal composition of the late Na+ current in human ventricular cardiomyocytes. Cardiovasc Res (2005) 1.29
Down-regulation of sodium current in chronic heart failure: effect of long-term therapy with carvedilol. Cell Mol Life Sci (2002) 1.20
[Na+]i and the driving force of the Na+/Ca2+-exchanger in heart failure. Cardiovasc Res (2003) 1.12
Relationship between action potential, contraction-relaxation pattern, and intracellular Ca2+ transient in cardiomyocytes of dogs with chronic heart failure. Cell Mol Life Sci (1998) 1.12
Post-transcriptional alterations in the expression of cardiac Na+ channel subunits in chronic heart failure. J Mol Cell Cardiol (2004) 1.11
Spontaneous and inducible ventricular arrhythmias in a canine model of chronic heart failure: relation to haemodynamics and sympathoadrenergic activation. Eur Heart J (1992) 1.05
QT interval dispersion as a predictor of arrhythmic events in congestive heart failure. Importance of aetiology. Eur Heart J (1998) 0.99
Blockade of cardiac sodium channels. Competition between the permeant ion and antiarrhythmic drugs. J Clin Invest (1992) 0.98
Relations among heart failure severity, left ventricular loading conditions, and repolarization length in advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol (2003) 0.93
Relationship between external load and isolated myocyte contractile function with CHF in pigs. Am J Physiol (1997) 0.92
Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation (2004) 4.13
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol (2013) 3.90
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation (2007) 2.90
Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation (2012) 2.78
Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylation. Cardiovasc Res (2008) 2.66
Mitral valve surgery in heart failure: insights from the Acorn Clinical Trial. J Thorac Cardiovasc Surg (2006) 2.62
Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol (2008) 2.49
Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther (2006) 2.21
An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol (2008) 2.09
Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol (2010) 2.04
Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm (2011) 2.02
Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol (2004) 1.94
Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest (2006) 1.94
Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther (2004) 1.88
Gating of the late Na+ channel in normal and failing human myocardium. J Mol Cell Cardiol (2002) 1.88
Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation (2008) 1.83
Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol (2009) 1.78
Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol (2007) 1.77
Effect of adjustable passive constraint on the failing left ventricle: a finite-element model study. Ann Thorac Surg (2010) 1.76
Reactive oxygen species-activated Ca/calmodulin kinase IIδ is required for late I(Na) augmentation leading to cellular Na and Ca overload. Circ Res (2011) 1.69
Nav1.5-dependent persistent Na+ influx activates CaMKII in rat ventricular myocytes and N1325S mice. Am J Physiol Cell Physiol (2011) 1.69
Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther (2004) 1.66
Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation. Circ Res (2002) 1.64
Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation (2002) 1.63
A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging (2009) 1.63
Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res (2008) 1.62
Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol (2008) 1.60
Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J (2013) 1.60
Low carbohydrate/high-fat diet attenuates cardiac hypertrophy, remodeling, and altered gene expression in hypertension. Hypertension (2006) 1.56
Mechanisms of heart failure with well preserved ejection fraction in dogs following limited coronary microembolization. Cardiovasc Res (2004) 1.53
Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol (2004) 1.52
Differential effects of saturated and unsaturated fatty acid diets on cardiomyocyte apoptosis, adipose distribution, and serum leptin. Am J Physiol Heart Circ Physiol (2006) 1.52
CVT-4325 inhibits myocardial fatty acid uptake and improves left ventricular systolic function without increasing myocardial oxygen consumption in dogs with chronic heart failure. Cardiovasc Drugs Ther (2007) 1.52
Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation (2003) 1.51
Deranged sodium to sudden death. J Physiol (2015) 1.51
Pathophysiology and pharmacology of the cardiac "late sodium current.". Pharmacol Ther (2008) 1.50
Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics. JACC Cardiovasc Imaging (2009) 1.48
Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. Eur J Heart Fail (2006) 1.47
Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm (2008) 1.46
A(2B) adenosine receptors increase cytokine release by bronchial smooth muscle cells. Am J Respir Cell Mol Biol (2003) 1.46
Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol (2007) 1.42
Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res (2012) 1.39
Clinical evaluation of the CorCap Cardiac Support Device in patients with dilated cardiomyopathy. Ann Thorac Surg (2007) 1.37
Modulation of late sodium current by Ca2+, calmodulin, and CaMKII in normal and failing dog cardiomyocytes: similarities and differences. Am J Physiol Heart Circ Physiol (2008) 1.36
Targeting myocardial substrate metabolism in heart failure: potential for new therapies. Eur J Heart Fail (2012) 1.36
Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol (2008) 1.35
Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am J Physiol Heart Circ Physiol (2003) 1.32
Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol (2006) 1.30
Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther (2005) 1.28
An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. J Pharmacol Exp Ther (2005) 1.27
Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol (2010) 1.27
Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail (2010) 1.27
Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm (2007) 1.27
Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J Am Coll Cardiol (2010) 1.26
A method for automatically optimizing medical devices for treating heart failure: designing polymeric injection patterns. J Biomech Eng (2009) 1.25
A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet (2006) 1.24
Use-dependent block of cardiac late Na(+) current by ranolazine. Heart Rhythm (2009) 1.23
Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure. J Mol Cell Cardiol (2006) 1.21
Effect of a specific and selective A(2B) adenosine receptor antagonist on adenosine agonist AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma. J Pharmacol Exp Ther (2006) 1.19
Late sodium current contributes to diastolic cell Ca2+ accumulation in chronic heart failure. J Physiol Sci (2010) 1.18
Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol (2004) 1.17
Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PLoS One (2010) 1.16
Abnormal mitochondrial respiration in skeletal muscle in patients with peripheral arterial disease. J Vasc Surg (2003) 1.16
Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. Cardiovasc Res (2007) 1.15
Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol (2009) 1.13
Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res (2002) 1.12
Upregulation of glucose-6-phosphate dehydrogenase and NAD(P)H oxidase activity increases oxidative stress in failing human heart. J Card Fail (2007) 1.11
Post-transcriptional alterations in the expression of cardiac Na+ channel subunits in chronic heart failure. J Mol Cell Cardiol (2004) 1.11
Mitral valve repair in heart failure: five-year follow-up from the mitral valve replacement stratum of the Acorn randomized trial. J Thorac Cardiovasc Surg (2011) 1.11
A2B adenosine receptors induce IL-19 from bronchial epithelial cells, resulting in TNF-alpha increase. Am J Respir Cell Mol Biol (2006) 1.10
Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol (2004) 1.09
Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine. Channels (Austin) (2008) 1.09
Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent block. Am J Physiol Heart Circ Physiol (2011) 1.08
Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol (2003) 1.07
Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J Am Coll Cardiol (2007) 1.05
High intake of saturated fat, but not polyunsaturated fat, improves survival in heart failure despite persistent mitochondrial defects. Cardiovasc Res (2011) 1.05
Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol (2009) 1.05
Rapid kinetic interactions of ranolazine with HERG K+ current. J Cardiovasc Pharmacol (2008) 1.04
Polymer-based restoration of left ventricular mechanics. Cell Transplant (2012) 1.04
Sustained benefits of the CorCap Cardiac Support Device on left ventricular remodeling: three year follow-up results from the Acorn clinical trial. Ann Thorac Surg (2007) 1.04
Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure. J Am Coll Cardiol (2008) 1.03
The arrhythmogenic consequences of increasing late INa in the cardiomyocyte. Cardiovasc Res (2013) 1.03
Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol (2008) 1.03
Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart. Am J Physiol Heart Circ Physiol (2009) 1.03
Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization. Circulation (2011) 1.03
Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study. Clin Cardiol (2011) 1.03
Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Fail Rev (2014) 1.03
Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol (2009) 1.02
Beneficial effects of the CorCap cardiac support device: five-year results from the Acorn Trial. J Thorac Cardiovasc Surg (2011) 1.02
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev (2009) 1.02
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J (2012) 1.02
Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. Naunyn Schmiedebergs Arch Pharmacol (2007) 1.02
The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease. FASEB J (2012) 1.01